RVPH (Reviva Pharmaceuticals Holdings) Institutional Ownership: 23.58% (As of Jul. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RVPH Reviva Pharmaceuticals Holdings Inc RVPH
22 GF Score
Price $0.47
! 1 Warning Sign
View Full Analysis

What is Reviva Pharmaceuticals Holdings Institutional Ownership?

Reviva Pharmaceuticals Holdings RVPH +11.90% 22 Institutional Ownership is 23.58% as of Jul. 23, 2026. GuruFocus rates RVPH with a GF Score™ of 22/100. The stock has 1 warning sign investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Reviva Pharmaceuticals Holdings's institutional ownership is 23.58%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Reviva Pharmaceuticals Holdings's Insider Ownership is 20.51%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Reviva Pharmaceuticals Holdings's Float Percentage Of Total Shares Outstanding is 97.52%.

Reviva Pharmaceuticals Holdings Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Reviva Pharmaceuticals Holdings's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Reviva Pharmaceuticals Holdings Institutional Ownership Chart

Reviva Pharmaceuticals Holdings Historical Data

The historical data trend for Reviva Pharmaceuticals Holdings can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 8.46 8.84 8.88 4.91 4.79 4.71 2.27 2.26 1.00 0.70
RVPH
22GF Score
Reviva Pharmaceuticals Holdings Inc RVPH
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Reviva Pharmaceuticals Holdings Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 23.58% mean?
Reviva Pharmaceuticals Holdings (RVPH) has a Institutional Ownership of 23.58% as of Jul. 23, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Reviva Pharmaceuticals Holdings and its competitors.
Is Reviva Pharmaceuticals Holdings' Institutional Ownership too high?
Reviva Pharmaceuticals Holdings' current Institutional Ownership is 23.58%. Overall, Reviva Pharmaceuticals Holdings has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Reviva Pharmaceuticals Holdings' Institutional Ownership compare to AIM and BOLT?
Reviva Pharmaceuticals Holdings' Institutional Ownership of 23.58% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Reviva Pharmaceuticals Holdings and its competitors. Reviva Pharmaceuticals Holdings's current Institutional Ownership is 23.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Reviva Pharmaceuticals Holdings stock overvalued right now?
Reviva Pharmaceuticals Holdings (RVPH) has a current Institutional Ownership of 23.58%. The current Institutional Ownership is 23.58%. Reviva Pharmaceuticals Holdings' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Reviva Pharmaceuticals Holdings (RVPH), the current Institutional Ownership is 23.58% as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Reviva Pharmaceuticals Holdings Business Description

Address 10080 North Wolfe Road, Suite SW3-200, Cupertino, CA, USA, 95014
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063), which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis, and its other drug candidate is RP1208.
22GF Score

Get the complete analysis for RVPH

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.47
Price